
TotalEnergies Rejects Venture Global LNG Over Trust Issues
Feb 06, 2025 05:23 am UTC| Business
TotalEnergies (EPA:TTEF) declined long-term LNG supply deals with Venture Global due to trust concerns, CEO Patrick Pouyanné told Reuters. The French energy giant refused offers from Venture Globals Calcasieu Pass...

USPS Resumes China Shipments Amid De Minimis Policy Shift
Feb 06, 2025 05:20 am UTC| Business Politics
The U.S. Postal Service (USPS) has reinstated parcel shipments from China and Hong Kong after briefly suspending them due to President Donald Trumps removal of the de minimis duty exemption, which allowed retailers like...

Nissan Drops Merger Talks with Honda Amid Growing Differences
Feb 06, 2025 05:02 am UTC| Business
Nissan CEO Makoto Uchida has informed Honda CEO Toshihiro Mibe of the companys decision to withdraw from their memorandum of understanding (MOU) regarding a potential merger, according to a source familiar with the matter....

Asian Chip Stocks Surge as Nvidia, AI Investments Fuel Rally
Feb 06, 2025 05:02 am UTC| Technology Business
Asian semiconductor stocks climbed Thursday, following a strong rally in Nvidia (NASDAQ:NVDA) after major tech firms, including Alphabet (NASDAQ:GOOGL), Microsoft (NASDAQ:MSFT), and Meta (NASDAQ:META), projected higher...

DeepSeek Expands with Competitive Salaries Amid AI Boom
Feb 06, 2025 05:02 am UTC| Technology Business
Chinese AI startup DeepSeek is making waves with its R1 model and a major hiring push, offering lucrative salaries to top AI talent. According to China Fund News, the company is recruiting AI researchers with monthly...

GSK Raises 2031 Sales Forecast to £40B Amid Strong Specialty Medicine Growth
Feb 05, 2025 12:19 pm UTC| Business
GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion. The revision reflects confidence in its expanding specialty medicines portfolio, late-stage...

Novo Nordisk Projects Slower Growth as Wegovy Demand Moderates
Feb 05, 2025 12:19 pm UTC| Business
Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its blockbuster obesity drug, Wegovy. The Danish pharmaceutical giant projects local currency sales growth...